Treventis attends Virtual AAIC 2020

Posted on

Treventis was well represented at the Alzheimer Association International Conference, running from Jul 27-31, 2020 (originally scheduled for Amsterdam, the Netherlands, and converted to virtual format due to COVID-19). CEO Christopher Barden, VP Research Marcia Taylor, CSO Mark Reed, and Chief Medical Officer Dr. Donald Weaver were delegates at the conference, the preeminent global annual […]

Treventis founders awarded funding for COVID-19 clinical trial

Posted on

LifeArc, a major UK-based charity, has announced funding for Treventis founders Dr. Donald Weaver, Christopher Barden, and Mark Reed to perform a repurposing clinical trial in inhaled furosemide for patients on mechanical ventilation due to COVID-19. This funding, awarded through a highly competitive rapid-response process starting on March 30, was awarded on Jun 30.  This […]

Treventis attends Virtual BIO Conference

Posted on

Not to be deterred by COVID-19, Treventis attended the BIO Digital International Convention (formerly scheduled for San Diego, California; instead held digitally) with more than 7,000 attendees and 64 countries represented.  This conference hosts delegates passionate about creating new opportunities to partner and collaborate on innovative drug projects aimed at improving the lives of patients. […]

Treventis attends 8th Neurodegenerative Drug Development Summit

Posted on

Treventis CSO Mark Reed was in attendance at the 8th Neurodegenerative Drug Development Summit (previously known as World CNS) held in Boston, Massachusetts from Feb 25-27. Among the speakers were Dementia Discovery Fund (and past Treventis advisor) Barbara Tate. This year’s main topics were progress in biomarker technologies and gene therapy, as well as emergence […]

Treventis Attends Tau2020 Conference

Posted on

Treventis VP Research Marcia Taylor has attended Tau2020 in Washington, DC, which is one of the world’s biggest conferences focusing on tau: the hallmark of many neurodegenerative diseases including Alzheimer’s disease. This conference covers not only on expanding the public’s awareness of the current tau research but also creating forward movement for it by engaging […]

Treventis founders publish new computational methodology for brain drug design

Posted on

Treventis founders Dr. Donald Weaver, Mark Reed, and Christopher Barden have supervised research at Toronto hospital UHN into new methods for predicting blood-brain permeability.  This research has culminated in two recent papers. Two papers by primary author and UHN postdoctoral associate Mayuri Gupta discuss the Blood-Brain Barrier (BBB) and the Brain Exposure Efficiency (BEE) scoring […]

Treventis attends BioPort Atlantic Conference

Posted on

Treventis CEO Christopher Barden attended BioPort, Atlantic Canada’s largest health and life sciences event in Halifax, Nova Scotia. BioPort is the region’s annual forum for education, information, and inspiration of the Atlantic Canadian life sciences ecosystem. At the event, Dr. Barden networked with the local community about Treventis and particularly as regards its Halifax-based butyrylcholinesterase […]

Treventis attends the 2nd Neuromuscular Drug Development Summit (NMD)

Posted on

CEO Christopher Barden attended the NMD Summit in Boston, Massachusetts, where he spoke with therapeutic and diagnostic companies that are working in the areas of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and muscular dystrophy, as well as other rare diseases with neuromuscular symptoms. This year’s summit surveyed biomarkers, clinically meaningful endpoints, and regulatory challenges […]

Treventis scientists visit Society for Neuroscience conference

Posted on

Treventis was represented at the 50th Society for Neuroscience Conference in Chicago, Illinois, one of the world’s largest conferences dedicated to brain research. Among the topics addressed in Chicago: mouse models of Alzheimer’s disease and other neurodegenerative disorders; seeding (Tau & Aβ) models; and new developments in the therapeutic landscape for AD.  Treventis has an […]